Start with what PALTmed published—and what it did not
PALTmed listed its Framework for Evaluating External Products and Services as an August 24 practice resource. The document says PALTmed's CMO Network developed it through discussion and draft review in early 2026 and endorsed the final version in June. Its intended users include medical and facility leaders evaluating outside offerings in post-acute and long-term care.
The framework is broad by design. It names clinical technology, remote monitoring, artificial intelligence tools, pharmacy or therapeutic services, staffing support, quality-improvement tools, and workflow or documentation platforms. It then organizes review around five pillars: standards and quality, clinical and operational fit, compliance and legal risk, financial and strategic impact, and vendor credibility and transparency.
PALTmed presents the document as guidance; it does not claim regulatory, certification, scoring, or product-endorsement status. It does not show that a named offering improves outcomes, meets a legal requirement, protects health information, fits a facility, or will survive implementation. Those questions still require evidence from the responsible parties and review under the facility's own process.
Place the consultant pharmacist on the right side of the table
An independent consultant pharmacist might help a facility evaluate a medication workflow, supply clinical context for a software decision, or be the outside service under review. Those roles should not collapse. The framework gives the CMO or medical director a major clinical-review role and calls for interdisciplinary input; it does not address or assign consultant-pharmacist purchasing authority.
PALTmed says a CMO or medical director should recuse and seek another clinical source when a potential conflict exists. A small consultant pharmacy practice can apply the same logic: record whether it is advising, selling, referring, implementing, or measuring the service, then route the final decision to the appropriate authority. Disclosure does not turn a commercial interest into independent evidence.
Turn five pillars into one decision record
The framework does not prescribe a form. The following compact record is an editorial way to make its questions testable without building another binder:
- Job and population: State the exact problem, setting, intended users, resident population, and work that remains outside the proposed product or service.
- Claim and evidence: Put each material claim beside its source, population, date, limitation, and the person responsible for verifying it. Keep a vendor statement visibly attributed.
- Implementation: Name the local champion, workflow owner, training burden, physical or technical dependencies, fallback, and support path when staff or conditions change.
- Risk and data: Identify the responsible legal, compliance, privacy, security, clinical, and contracting reviews; list what information enters, leaves, remains available, and is destroyed at exit.
- Cost and value: Record direct and indirect costs, who does the work, who receives the proposed benefit, the baseline, and the metric that would show whether value appeared.
- Decision gate: Set the evidence due date, pilot period, expansion threshold, stop condition, unresolved questions, and person authorized to decide.
Make the pilot capable of stopping
PALTmed suggests screening first, using a fuller interdisciplinary evaluation when the offering clears that screen, and considering a limited pilot when full deployment carries meaningful cost or risk. It also says a pilot should have clear success measures and a timeline, and notes that a pilot may need to be distinguished from research for institutional-review purposes.
A pilot is informative only when ordinary, disappointing, and exception results can all be recorded. Before launch, preserve the baseline; define each measure's numerator, denominator, exclusions, and observation window; name the exception owner; and decide what pauses or ends the test. Use de-identified planning material where resident-level information is unnecessary, and keep permitted clinical data inside the approved process.
Do not let adoption become the measure of success. Staff logging in, a dashboard filling up, or a vendor completing training shows activity. It does not by itself establish safer care, less burden, better follow-up, reliable exchange, or sustainable cost. The decision record should make that distinction visible before enthusiasm and sunk effort make stopping harder.
End with an evidence packet, not a smoother promise
The framework asks about evidence, similar PALTC references, pricing and performance transparency, responsiveness, and willingness to support a limited rollout. A practice offering a pharmacy service can arrive with a bounded scope, attributable evidence, responsibilities, measures, pricing assumptions, conflict disclosure, data boundaries, and an exit path. A practice helping buy a tool can request the same items instead of accepting a feature list as the evaluation.
PALTmed's framework is not presented as a validated scoring instrument, and it assigns no weights or pass marks to the five pillars. Local leaders still decide which risks, dependencies, and benefits matter. A modest next step is to choose one offering, write one decision record, and identify which promised answer remains unsupported before anyone calls the pilot ready.